127 related articles for article (PubMed ID: 19955335)
1. Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice.
Bueno-de-Mesquita JM; Sonke GS; van de Vijver MJ; Linn SC
Ann Oncol; 2011 Sep; 22(9):2021-2030. PubMed ID: 19955335
[TBL] [Abstract][Full Text] [Related]
2. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
Bueno-de-Mesquita JM; van Harten WH; Retel VP; van 't Veer LJ; van Dam FS; Karsenberg K; Douma KF; van Tinteren H; Peterse JL; Wesseling J; Wu TS; Atsma D; Rutgers EJ; Brink G; Floore AN; Glas AM; Roumen RM; Bellot FE; van Krimpen C; Rodenhuis S; van de Vijver MJ; Linn SC
Lancet Oncol; 2007 Dec; 8(12):1079-1087. PubMed ID: 18042430
[TBL] [Abstract][Full Text] [Related]
3. Validation of 70-gene prognosis signature in node-negative breast cancer.
Bueno-de-Mesquita JM; Linn SC; Keijzer R; Wesseling J; Nuyten DS; van Krimpen C; Meijers C; de Graaf PW; Bos MM; Hart AA; Rutgers EJ; Peterse JL; Halfwerk H; de Groot R; Pronk A; Floore AN; Glas AM; Van't Veer LJ; van de Vijver MJ
Breast Cancer Res Treat; 2009 Oct; 117(3):483-95. PubMed ID: 18819002
[TBL] [Abstract][Full Text] [Related]
4. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
[TBL] [Abstract][Full Text] [Related]
5. A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.
Jézéquel P; Campone M; Roché H; Gouraud W; Charbonnel C; Ricolleau G; Magrangeas F; Minvielle S; Genève J; Martin AL; Bataille R; Campion L
Breast Cancer Res Treat; 2009 Aug; 116(3):509-20. PubMed ID: 19020972
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
[TBL] [Abstract][Full Text] [Related]
7. Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms.
Drukker CA; Nijenhuis MV; Bueno-de-Mesquita JM; Retèl VP; van Harten WH; van Tinteren H; Wesseling J; Schmidt MK; Van't Veer LJ; Sonke GS; Rutgers EJ; van de Vijver MJ; Linn SC
Breast Cancer Res Treat; 2014 Jun; 145(3):697-705. PubMed ID: 24760482
[TBL] [Abstract][Full Text] [Related]
8. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.
Mook S; Schmidt MK; Viale G; Pruneri G; Eekhout I; Floore A; Glas AM; Bogaerts J; Cardoso F; Piccart-Gebhart MJ; Rutgers ET; Van't Veer LJ;
Breast Cancer Res Treat; 2009 Jul; 116(2):295-302. PubMed ID: 18661261
[TBL] [Abstract][Full Text] [Related]
9. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.
Wang Y; Klijn JG; Zhang Y; Sieuwerts AM; Look MP; Yang F; Talantov D; Timmermans M; Meijer-van Gelder ME; Yu J; Jatkoe T; Berns EM; Atkins D; Foekens JA
Lancet; 2005 Feb 19-25; 365(9460):671-9. PubMed ID: 15721472
[TBL] [Abstract][Full Text] [Related]
10. Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.
Tutt A; Wang A; Rowland C; Gillett C; Lau K; Chew K; Dai H; Kwok S; Ryder K; Shu H; Springall R; Cane P; McCallie B; Kam-Morgan L; Anderson S; Buerger H; Gray J; Bennington J; Esserman L; Hastie T; Broder S; Sninsky J; Brandt B; Waldman F
BMC Cancer; 2008 Nov; 8():339. PubMed ID: 19025599
[TBL] [Abstract][Full Text] [Related]
11. Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer.
Kok M; Koornstra RH; Mook S; Hauptmann M; Fles R; Jansen MP; Berns EM; Linn SC; Van 't Veer LJ
Breast; 2012 Dec; 21(6):769-78. PubMed ID: 22738860
[TBL] [Abstract][Full Text] [Related]
12. A molecular signature of the Nottingham prognostic index in breast cancer.
Yu K; Lee CH; Tan PH; Hong GS; Wee SB; Wong CY; Tan P
Cancer Res; 2004 May; 64(9):2962-8. PubMed ID: 15126326
[TBL] [Abstract][Full Text] [Related]
13. Combining biological gene expression signatures in predicting outcome in breast cancer: An alternative to supervised classification.
Nuyten DS; Hastie T; Chi JT; Chang HY; van de Vijver MJ
Eur J Cancer; 2008 Oct; 44(15):2319-29. PubMed ID: 18715778
[TBL] [Abstract][Full Text] [Related]
14. A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma.
Sun JM; Han W; Im SA; Kim TY; Park IA; Noh DY; Heo DS; Bang YJ; Choe KJ; Kim NK
Cancer; 2004 Dec; 101(11):2516-22. PubMed ID: 15517588
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.
Aalders KC; Kuijer A; Straver ME; Slaets L; Litiere S; Viale G; Van't Veer LJ; Glas AM; Delorenzi M; van Dalen T; Tryfonidis K; Piccart MJ; Cardoso F; Rutgers EJ;
Eur J Cancer; 2017 Jul; 79():98-105. PubMed ID: 28477490
[TBL] [Abstract][Full Text] [Related]
16. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
Buyse M; Loi S; van't Veer L; Viale G; Delorenzi M; Glas AM; d'Assignies MS; Bergh J; Lidereau R; Ellis P; Harris A; Bogaerts J; Therasse P; Floore A; Amakrane M; Piette F; Rutgers E; Sotiriou C; Cardoso F; Piccart MJ;
J Natl Cancer Inst; 2006 Sep; 98(17):1183-92. PubMed ID: 16954471
[TBL] [Abstract][Full Text] [Related]
17. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
18. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
19. Validation and problems of St-Gallen recommendations of adjuvant therapy for node-negative invasive breast cancer in Japanese patients.
Iwamoto E; Fukutomi T; Akashi-Tanaka S
Jpn J Clin Oncol; 2001 Jun; 31(6):259-62. PubMed ID: 11463803
[TBL] [Abstract][Full Text] [Related]
20. A gene-expression signature as a predictor of survival in breast cancer.
van de Vijver MJ; He YD; van't Veer LJ; Dai H; Hart AA; Voskuil DW; Schreiber GJ; Peterse JL; Roberts C; Marton MJ; Parrish M; Atsma D; Witteveen A; Glas A; Delahaye L; van der Velde T; Bartelink H; Rodenhuis S; Rutgers ET; Friend SH; Bernards R
N Engl J Med; 2002 Dec; 347(25):1999-2009. PubMed ID: 12490681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
